Should you buy these 3 healthcare shares?

Good healthcare shares are almost always in high demand, with many investors perceiving that healthcare is both a defensive business and likely to see significant growth over the long term. Here’s my take on whether these 3 well-known healthcare operators are a buy today:

CSL Limited (ASX: CSL)

CSL is a researcher and manufacturer of blood products for immune therapies and coagulation disorders, among others. It also owns a vaccine business, Seqirus, which has been unprofitable in recent times and is being turned around. CSL also has an extensive research pipeline of future treatments for things like heart attacks and sickle-cell disease. The only drawback is the price, as CSL’s prospects are well known and it is commonly regarded as Australia’s best company. If I knew I could take a 10-year time frame, I’d consider buying a small stake in CSL today, with the view to adding it on any price weakness.

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)

Fisher & Paykel is a designer and manufacturer of oxygen masks and breathing apparatus; a booming industry in the USA, its major market. Although seemingly expensive, Fisher & Paykel is moving manufacturing to Mexico and building large factories to meet anticipated future demand. I’d consider taking a small stake in the company at today’s prices, although a patent infringement lawsuit and counter-suit against ResMed Inc. (CHESS) (ASX: RMD) adds extra risk. Like CSL above, Fisher & Paykel is quite richly priced and I’d suggest buyers start with a small stake and a view to opportunistically increasing it over time.

Sirtex Medical Limited (ASX: SRX)

Sirtex shares have been hit hard by the failure of several important clinical trials, as well as the firing of former CEO Gilman Wong for improper share trading. The clinical trials mean that Sirtex is unlikely to expand the ‘indications’ (potential uses) for its SIR-Spheres treatment which ultimately means a smaller potential market. The new CEO has several ideas for cutting costs and growing sales in the current market, but were I not a shareholder already, I’d be inclined to wait on the fence while I see how it pans out.

If You Can Buy Just 1 Dividend Share, This Is It

You’re missing out on what is arguably the biggest factor in generating huge stock market returns. But don’t worry, I'm going to tell you how to get in on what might be the simplest way to a carefree retirement.

We all know that dividend-paying shares are an excellent way to build long-term wealth. But do you know just HOW great?

To learn the name of this incredible share opportunity, and why The Motley Fool’s team of analysts think its dividend is likely to GROW in the years ahead, simply click here.

Motley Fool contributor Sean O'Neill owns shares of Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.